Zentalis Pharmaceuticals (NASDAQ:ZNTL) Price Target Lowered to $8.00 at Guggenheim

Zentalis Pharmaceuticals (NASDAQ:ZNTL) had its price target lowered by Guggenheim from $12.00 to $8.00 in a research report released on Friday morning,Benzinga reports. The brokerage currently has a buy rating on the stock.

Other equities research analysts also recently issued research reports about the company. Oppenheimer reaffirmed an “outperform” rating and issued a $20.00 target price on shares of Zentalis Pharmaceuticals in a research report on Monday, September 16th. Wedbush upgraded Zentalis Pharmaceuticals from an “underperform” rating to a “neutral” rating and set a $4.00 price target for the company in a report on Monday, August 12th. Finally, HC Wainwright reiterated a “buy” rating and set a $20.00 price objective on shares of Zentalis Pharmaceuticals in a research note on Friday. Five research analysts have rated the stock with a hold rating and four have assigned a buy rating to the company’s stock. Based on data from MarketBeat.com, the stock currently has an average rating of “Hold” and a consensus target price of $10.00.

Zentalis Pharmaceuticals Stock Performance

Shares of NASDAQ:ZNTL traded down $0.48 during midday trading on Friday, hitting $3.47. 1,832,087 shares of the company’s stock traded hands, compared to its average volume of 1,566,191. The firm’s fifty day moving average price is $3.42 and its two-hundred day moving average price is $5.46. Zentalis Pharmaceuticals has a twelve month low of $2.66 and a twelve month high of $18.07.

Hedge Funds Weigh In On Zentalis Pharmaceuticals

A number of hedge funds have recently added to or reduced their stakes in ZNTL. Erste Asset Management GmbH acquired a new position in Zentalis Pharmaceuticals in the third quarter valued at approximately $37,000. Paloma Partners Management Co bought a new position in Zentalis Pharmaceuticals in the 3rd quarter valued at about $37,000. Anfield Capital Management LLC acquired a new position in Zentalis Pharmaceuticals during the 2nd quarter valued at about $40,000. Aigen Investment Management LP bought a new stake in shares of Zentalis Pharmaceuticals during the 3rd quarter worth about $41,000. Finally, Capstone Investment Advisors LLC bought a new position in shares of Zentalis Pharmaceuticals in the third quarter valued at approximately $48,000.

About Zentalis Pharmaceuticals

Zentalis Pharmaceuticals, Inc, a clinical-stage biopharmaceutical company, focuses on discovering and developing small molecule therapeutics for the treatment of various cancers. Its products candidatures include the ZN-c3, an inhibitor of WEE1, a protein tyrosine kinase for the treatment of inhibitor for advanced solid tumors and hematological malignancies; in Phase 2 clinical trial as a monotherapy for the treatment of uterine serous carcinoma indications; Phase 2 clinical trial in Cyclin E1 driven high-grade serous ovarian cancer, fallopian tube, or primary peritoneal cancer; Phase 1/2 clinical trial in combination with PARPi for platinum-resistant ovarian cancer; Phase 1b clinical trial in combination with chemotherapy in platinum-resistant ovarian, and peritoneal or fallopian tube cancer; Phase 1/2 clinical trial in combination with chemotherapy in relapsed or refractory osteosarcoma; Phase 1/2 clinical trial with encorafenib and cetuximab for mutant metastatic colorectal cancer; and Phase 1/2 clinical trial in combination with chemotherapy in pancreatic cancer.